Outcomes of Clazosentan Versus Fasudil in Aneurysmal Subarachnoid Hemorrhage Outside Japanese Pivotal Trial Criteria: An Exploratory RECOVER Subgroup Analysis
This exploratory RECOVER subgroup analysis suggests that clazosentan may offer favorable discharge outcomes compared to fasudil in aneurysmal subarachnoid hemorrhage patients excluded from pivotal Japanese trials (such as those aged ≥76, with WFNS grade V, or non-Fisher group 3), without a consistent increase in major adverse events, indicating these exclusion criteria should prompt individualized assessment rather than automatic avoidance.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When a blood vessel in the brain bursts, causing a sudden and severe bleed known as an aneurysmal subarachnoid hemorrhage, the immediate danger is the rupture itself. Once surgeons secure the broken vessel, a second, quieter threat often emerges days later: the brain's blood vessels can suddenly narrow, a condition called vasospasm. This narrowing restricts blood flow, starving brain tissue of oxygen and leading to further damage or stroke. For decades, doctors have relied on medications to prevent this narrowing, but the standard options have limitations. In Japan, a drug called fasudil has been the go-to treatment, yet researchers have long sought something more targeted. A newer medication, clazosentan, works by blocking a specific chemical signal that tells blood vessels to squeeze shut. While early large-scale trials showed clazosentan could reduce vessel narrowing, they excluded the most vulnerable patients—those who were very elderly, those with the most severe initial brain injury, or those with specific types of bleeding patterns. This left doctors in a difficult position, unsure if the new drug was safe or helpful for the very people who needed it most.
A team of researchers in Japan set out to resolve this uncertainty by looking at real-world data from patients who fell outside the strict rules of those earlier trials. They analyzed records from nearly 400 patients treated at various hospitals, comparing those who received the new drug, clazosentan, against those who received the standard treatment, fasudil. The study focused specifically on groups that had been left out of previous major studies: patients aged 76 or older, those with the most severe grade of initial brain injury, and those whose bleeding patterns did not match the "typical" profile seen in earlier trials. The goal was not to prove the drug worked perfectly in these groups, but to see if the benefits seen in younger, healthier patients disappeared or turned dangerous when applied to these more fragile populations.
The analysis revealed a consistent pattern across these difficult-to-treat groups. In patients aged 76 and older, those treated with clazosentan were more likely to leave the hospital with a good functional outcome compared to those on fasudil. While the numbers were small and the statistical certainty was not absolute, the trend pointed in the same positive direction as it did for younger patients. Similarly, in the group with the most severe initial brain injury, the drug did not cause harm and showed a tendency toward better results. Perhaps most notably, in patients with specific, complex bleeding patterns that had previously excluded them from trials, the new drug was associated with a significantly lower rate of the dangerous vessel narrowing and a higher rate of good recovery outcomes. In one specific subgroup of patients with complex bleeding, not a single person treated with clazosentan suffered from the delayed brain damage caused by vessel narrowing, whereas a notable portion of those on the standard drug did.
Crucially, the study also looked for signs that the new drug might be too harsh for these vulnerable patients. Doctors had worried that clazosentan might cause fluid to build up in the lungs or brain, or lead to dangerously low blood pressure, especially in the elderly. The data did not show a consistent increase in these serious side effects. While there were a few isolated incidents of new bleeding in the brain among the elderly patients on the new drug, the numbers were too small to declare a definitive risk, and the overall pattern did not suggest the drug was unsafe for these groups. The researchers emphasized that the absence of a clear safety signal in such a small study does not prove the drug is perfectly safe, but it does suggest that the fears of automatic harm were not borne out by the data.
The findings challenge the idea that strict trial rules should act as absolute barriers to treatment. The study suggests that being too old, having a severe injury, or having a specific type of bleeding should not automatically disqualify a patient from trying clazosentan. Instead, these factors should prompt doctors to weigh the potential benefits against the risks for each individual patient. The data indicates that the drug's ability to prevent vessel narrowing and improve outcomes likely extends beyond the narrow group of patients originally tested. While the study was observational and not a randomized experiment, the consistency of the results across different groups of difficult-to-treat patients offers a compelling reason to reconsider how these medications are used. It suggests that for many patients who were previously left without a clear path forward, a careful, monitored trial of the new drug could offer a better chance at recovery than the standard approach.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.